A comparative analysis of LEF-1 in odontogenic and salivary tumors

作者：Bilodeau Elizabeth A^*; Acquafondata Marie; Barnes E Leon; Seethala Raja R

来源：Human Pathology, 2015, 46(2): 255-259.

DOI：10.1016/j.humpath.2014.10.018

• LEF-1
• Lymphoid enhancer binding factor-1
• Salivary gland tumors
• Odontogenic tumors
• Basal cell adenocarcinoma
• Immunohistochemistry
• beta-Catenin

LEF-1 is a nuclear transcription factor of the Wnt pathway that regulates multipotent skin stem cell differentiation. beta-Catenin is considered a transcriptional coactivator that interacts with LEF-1. This study evaluates LEF-1 in a variety of odontogenic and salivary tumors and determines the prevalence of beta-catenin coexpression. Ninety-eight salivary gland tumors and 51 odontogenic tumors were evaluated for LEF-1 and beta-catenin immunohistochemical staining. Positivity was defined as at least 2+ intensity in more than 50% of tumor cells, which required a composite score of 6 or more. LEF-1 was positive in 64% (7/11) of calcifying cystic odontogenic tumors (CCOT). Nuclear beta-catenin was present in 82% (9/11) of CCOT. Coexpression of LEF-1 and nuclear beta-catenin was noted in all LEF-1 positive CCOT. Strong and diffuse LEF-1 expression was seen in 69% (11/16) of basal cell adenocarcinomas (BCAC) and 63% (5/8) of basal cell adenomas (BA). Nuclear beta-catenin was present in 50% (4/8) of BA and 43% (6/14) of BCAC. For BA, 4 of 5 LEF-1 positive tumors showed coexpression of beta-catenin, and for BCAC, 5 of 9 LEF-1 positive tumors showed coexpression. In conclusion, this study documents for the first time the presence of LEF-1 expression and nuclear beta-catenin coexpression in select basaloid salivary gland tumors and various odontogenic tumors. We demonstrate LEF-1 expression in both BA and BCAC preferentially over other salivary gland tumors suggesting some utility as a diagnostic marker.

• 出版日期2015-2